Routine Surveillance of Upper Urinary Tract Imaging for Diagnosing Upper Urinary Tract Urothelial Cancer Recurrence in Patients with Nonmuscle Invasive Bladder Cancer
CONCLUSION: Most patients experiencing upper urinary tract urothelial cancer recurrence were diagnosed by routine surveillance imaging, suggesting its clinical importance, especially for patients with nonmuscle invasive bladder cancer accompanied by a tumor size of ≥30 mm and carcinoma in situ.PMID:38807901 | PMC:PMC11132829 | DOI:10.1155/2024/5894288 (Source: Advances in Urology)
Source: Advances in Urology - May 29, 2024 Category: Urology & Nephrology Authors: Nobutaka Nishimura Makito Miyake Tatsuki Miyamoto Takuto Shimizu Tomomi Fujii Yosuke Morizawa Shunta Hori Daisuke Gotoh Yasushi Nakai Kazumasa Torimoto Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Erratum: [Corrigendum] Survival outcomes in patients with T3 ‑4aN0M0 glottic laryngeal squamous cell carcinoma and evaluation of postoperative radiotherapy
Oncol Lett. 2024 May 15;28(1):323. doi: 10.3892/ol.2024.14456. eCollection 2024 Jul.ABSTRACT[This corrects the article DOI: 10.3892/ol.2022.13554.].PMID:38807683 | PMC:PMC11130752 | DOI:10.3892/ol.2024.14456 (Source: Oncology Letters)
Source: Oncology Letters - May 29, 2024 Category: Cancer & Oncology Authors: Jian Zhou Yu Heng Yue Yang Xiaoke Zhu Liang Zhou Hongli Gong Chengzhi Xu Lei Tao Source Type: research
Regorafenib plus programmed death ‑1 inhibitors vs. regorafenib monotherapy in second‑line treatment for advanced hepatocellular carcinoma: A systematic review and meta‑analysis
In conclusion, R-P is superior to regorafenib monotherapy in terms of survival benefits and tumor response.PMID:38807680 | PMC:PMC11130614 | DOI:10.3892/ol.2024.14451 (Source: Oncology Letters)
Source: Oncology Letters - May 29, 2024 Category: Cancer & Oncology Authors: Zhao Li Jie Wang Jingbing Zhao Zhengwei Leng Source Type: research
Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus: A case report
Oncol Lett. 2024 May 17;28(1):332. doi: 10.3892/ol.2024.14465. eCollection 2024 Jul.ABSTRACTTremelimumab plus durvalumab (Dur/Tre) is the first-line treatment for advanced hepatocellular carcinoma (HCC) worldwide. The present report describes the case of a 68-year-old man diagnosed with advanced HCC and a bile duct tumor thrombus (BDTT) who achieved a complete response to Dur/Tre therapy. The BDTT progressed to the bifurcation of the left and right hepatic ducts. Over time, both the tumors and BDTT progressively decreased in size, and a complete response was confirmed using the Response Evaluation Criteria in Solid Tumors ...
Source: Oncology Letters - May 29, 2024 Category: Cancer & Oncology Authors: Nobuaki Ishihara Shohei Komatsu Masahiro Kido Hidetoshi Gon Kenji Fukushima Takeshi Urade Toshihiko Yoshida Keisuke Arai Hiroaki Yanagimoto Hirochika Toyama Takumi Fukumoto Source Type: research
Synchronous small cell neuroendocrine carcinoma of the cervix and immature ovarian teratoma: A case report and literature review
Oncol Lett. 2024 May 14;28(1):313. doi: 10.3892/ol.2024.14446. eCollection 2024 Jul.ABSTRACTThe onset of two synchronous primary malignancies of the female genital tract is uncommon; therefore, the simultaneous occurrence of cervical small cell neuroendocrine carcinoma and ovarian immature teratoma is rare. The present study describes the case of a woman with cervical small cell neuroendocrine carcinoma complicated by ovarian immature teratoma. The clinical manifestations, and the histopathological and immunophenotypic features of the patient are recorded. Furthermore, all PubMed-indexed cases of synchronous primary malign...
Source: Oncology Letters - May 29, 2024 Category: Cancer & Oncology Authors: Mingyu Xie Yongsen Li Hui Chen Qingping Jiang Hanzhen Xiong Source Type: research
miR ‑576‑3p/M‑phase phosphoprotein 8 axis regulates the malignant progression of hepatocellular carcinoma cells via the PI3K/Akt signaling pathway
In conclusion, the miR-576-3p/MPP8 axis regulates the proliferation, migration, and invasion of liver cancer cells through the PI3K/Akt signaling pathway. These findings lead novel insights into HCC progression, and propose MPP8 as a potential therapeutic target for HCC.PMID:38807669 | PMC:PMC11130756 | DOI:10.3892/ol.2024.14460 (Source: Oncology Letters)
Source: Oncology Letters - May 29, 2024 Category: Cancer & Oncology Authors: Nannan Zhang Mengyi Chi Weili Pan Congying Zhang Yali Wang Xiaoyan Gao Chunying Bai Xianjun Liu Source Type: research
Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st ‑ or 2nd‑line treatment
In conclusion, patients receiving 2nd LEN after treatment with Atez/BV are at an increased risk of hypothyroidism.PMID:38807665 | PMC:PMC11130744 | DOI:10.3892/ol.2024.14464 (Source: Oncology Letters)
Source: Oncology Letters - May 29, 2024 Category: Cancer & Oncology Authors: Michio Kimura Shiori Yamada Makiko Go Satoshi Yasuda Hidenori Toyoda Eiseki Usami Source Type: research
Effective neoadjuvant immunotherapy and chemotherapy in stage IIIA adenosquamous carcinoma of the lung with a complete response and surgical success: A case report
Oncol Lett. 2024 May 14;28(1):314. doi: 10.3892/ol.2024.14448. eCollection 2024 Jul.ABSTRACTThere has been rapid advancement in the development of neoadjuvant therapy for non-small cell lung cancer (NSCLC), which holds great promise as an effective treatment strategy. Some clinical trials have confirmed that immunotherapy in combination with chemotherapy can be a recommended first-line regimen for neoadjuvant treatment of NSCLC. The present study describes the case of a male patient aged 65 years who was diagnosed with stage IIIA (cT2N2M0) adenosquamous carcinoma of the lung. After the administration of two cycles of neoad...
Source: Oncology Letters - May 29, 2024 Category: Cancer & Oncology Authors: Chen Song Yuhui Nie Tianzi Liu Xintong Peng Jing Liu Ziwen Zhou Yan Huang Source Type: research
The role of EUS-guided iodine-125 seed implantation in patients with unresectable ampullary cancer after relief of obstructive jaundice
CONCLUSIONS: Longer intervention interval for biliary obstruction and survival as well as better stent patency and prolonged time to duodenal obstruction could be achieved by implanting 125I seeds combined with biliary stent in patients with unresectable ampullary cancer.PMID:38808212 | PMC:PMC11129651 | DOI:10.5114/jcb.2024.139279 (Source: Journal of Contemporary Brachytherapy)
Source: Journal of Contemporary Brachytherapy - May 29, 2024 Category: Cancer & Oncology Authors: Ting-Ting Cui Xin-Xiang Guo Bai-Rong Li Zi-Kai Wang Nian-Jun Xiao Fang Liu Xiang-Dong Wang Wen Li Source Type: research
Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer
J Contemp Brachytherapy. 2024 Apr;16(2):150-155. doi: 10.5114/jcb.2024.139103. Epub 2024 Apr 23.ABSTRACTPatients with primary tumor progression after stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) have a second chance at complete tumor eradication with salvage local therapies, including lung resection, repeat course of SBRT, and percutaneous ablative therapies. In this paper, we presented our institution's initial experience with percutaneous high-dose-rate (HDR) brachyablation for a relapsed stage I NSCLC that had been treated with SBRT 4.3 years earlier. Lung tumor measuring app...
Source: Journal of Contemporary Brachytherapy - May 29, 2024 Category: Cancer & Oncology Authors: Trudy C Wu Alan Lee Robert Suh Talia C Oughourlian Fereidoun Abtin Mary Ann Hagio Sang-June Park Albert J Chang Drew Moghanaki Source Type: research
Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa
We report the case of a 19-year-old female patient with RDBE and inoperable locally advanced cSCC of the left arm. Because of the lack of therapy options, therapy with cemiplimab was started at a dose of 350 mg administered intravenously every 3 weeks. A confirmed clinical response was observed after the second cycle of treatment with no toxicity. During follow-up, the patient had a notable clinical response with no auto-immune adverse reactions. This shows that cemiplimab has a good safety profile for cSCC in patients with RDEB and is a valuable therapy option.PMID:38808531 (Source: Acta Dermatovenerologica Alpina, Panonica, et Adriatica)
Source: Acta Dermatovenerologica Alpina, Panonica, et Adriatica - May 29, 2024 Category: Dermatology Authors: Daniel Ciurescu Simina Condruz Marius Irimie Source Type: research
A study on expression of programmed death ligand-1 in small cell lung carcinoma and correlation with clinicopathological parameters
Pol J Pathol. 2024;75(1):25-35. doi: 10.5114/pjp.2024.136281.ABSTRACTSmall cell lung carcinoma (SCLC) is characterized by rapid growth and an aggressive clinical course. Standard therapy regimes have limited effects on disease course; therefore the prognosis of SCLC is poor. In the current study, the frequency of programmed death ligand 1 (PD-L1) expression in SCLC and its correlation with clinico-pathological features were evaluated. The study included 100 cases of SCLC wherein testing for PD-L1 was done with the SP263 clone on the Ventana benchmark XT system. Cases with > 1% PD-L1 expression in tumour cells or immune ...
Source: Polish Journal of Pathology - May 29, 2024 Category: Pathology Authors: Sudha Sudha Saumya Shukla Nuzhat Husain Hemant Kumar Rahul Kumar Pandey Surya Kant Source Type: research
Radiotherapy for parotid cancer: 10 years of experience in a single center
Conclusions:</b> Acceptable long-term results are obtained with surgery combined with radiotherapy. Surgical resection remains essential for parotid cancer, given the disappointing results of treatment with radiotherapy alone.</br>.PMID:38808641 (Source: Cancer Control)
Source: Cancer Control - May 29, 2024 Category: Cancer & Oncology Authors: Amine Lachgar Guy N'Da Karima Nouni Hanan El Kacemi Tayeb Kebdani Khalid Hassouni Source Type: research
The role of EUS-guided iodine-125 seed implantation in patients with unresectable ampullary cancer after relief of obstructive jaundice
CONCLUSIONS: Longer intervention interval for biliary obstruction and survival as well as better stent patency and prolonged time to duodenal obstruction could be achieved by implanting 125I seeds combined with biliary stent in patients with unresectable ampullary cancer.PMID:38808212 | PMC:PMC11129651 | DOI:10.5114/jcb.2024.139279 (Source: Cancer Control)
Source: Cancer Control - May 29, 2024 Category: Cancer & Oncology Authors: Ting-Ting Cui Xin-Xiang Guo Bai-Rong Li Zi-Kai Wang Nian-Jun Xiao Fang Liu Xiang-Dong Wang Wen Li Source Type: research
Delayed metastatic endometrial carcinoma mimicking primary colon adenocarcinoma: A surprise histopathological finding
We describe a rare case of metastatic endometrial cancer in the colon presenting 5 years post radical hysterectomy and adjuvant radiotherapy in a 62-year-old female. She presented with a 1-week history of right upper quadrant pain, with no other associated symptoms. She was presumed to have a primary colorectal cancer based on her colonoscopy and CT findings; later proven otherwise by immunohistochemistry (IHC). Endometrial cancer metastasis to the colon is rare, thus misdiagnosis can easily occur. Currently, there are 6 similar cases reported in the literature, all occurring in the absence of colorectal endometriosis. Thi...
Source: Clinical Colorectal Cancer - May 29, 2024 Category: Cancer & Oncology Authors: Hui Yuan Foong Jian Blundell Cameron Law Ross Warner Source Type: research
